Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.49 |
| ▸ | TXNRD3 | Q86VQ6 | 1/20 | 0.49 |
| ▸ | TXNRD2 | Q9NNW7 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.47 |
| ▸ | APEX1 | P27695 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | NOS3 | P29474 | 1/20 | 0.47 |
| ▸ | NOS1 | P29475 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | NOS2 | P35228 | 1/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | BLM | P54132 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21359970 | 0.91 | POLB (0.42) | TXNRD1TXNRD3TXNRD2POLBTDP1 | |
| Phosphoramidic Acid SCHEMBL312859 | 0.89 | POLB (0.41) | TXNRD1TXNRD3TXNRD2POLBTDP1 | |
| Morpholine SCHEMBL27607357 | 0.86 | POLB (0.41) | TXNRD1TXNRD3TXNRD2POLBTDP1 | |
| SCHEMBL28326417 | 0.86 | MEN1 (0.39) | TXNRD1TXNRD3TXNRD2POLBTDP1 | |
| SCHEMBL29395442 | 0.83 | POLB (0.46) | TXNRD1TXNRD3TXNRD2POLBTDP1 | |
| SCHEMBL28202812 | 0.78 | PARP1 (0.57) | TXNRD1TXNRD3TXNRD2POLBTDP1 | |
| SCHEMBL5675915 | 0.78 | CLK1 (0.50) | POLBTDP1CYP3A4APEX1MAPT | |
| SCHEMBL6142552 | 0.76 | CYP3A4 (0.46) | TDP1CYP3A4MAPTMEN1CYP1A2 | |
| Nitric Acid SCHEMBL14695341 | 0.76 | CYP3A4 (0.39) | TXNRD1TXNRD3TXNRD2POLBTDP1 | |
| SCHEMBL4518440 | 0.75 | ALDH1A1 (0.48) | TXNRD1TXNRD3TXNRD2POLBTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1059 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12630851-B2 | Polynucleotide modification methods | OXFORD NANOPORE TECHNOLOGIES PLC (GB) | 2026-05-19 | — | — | US | claimed |
| US-12624387-B2 | Method for reducing primer dimer formation and increasing amplification efficiency | SEEGENE, INC. (KR) | 2026-05-12 | — | — | US | claimed |
| US-12584168-B2 | Sample preparation method | OXFORD NANOPORE TECHNOLOGIES PLC (GB) | 2026-03-24 | — | — | US | claimed |
| US-12371736-B2 | TD probe and its uses | SEEGENE, INC. (KR) | 2025-07-29 | — | — | US | claimed |
| WO-2024136630-A1 | METHOD FOR SEQUENCE HOMOLOGY SEARCH OF NUCLEOTIDE DATABASE | 주식회사 씨젠 | 2024-06-27 | — | — | WO | claimed |
| EP-4293127-A2 | METHOD FOR REDUCING PRIMER DIMER FORMATION AND INCREASING AMPLIFICATION EFFICIENCY | Seegene, Inc. (KR) | 2023-12-20 | — | — | EP | claimed |
| EP-4001428-B1 | METHOD FOR REDUCING PRIMER DIMER FORMATION AND INCREASING AMPLIFICATION EFFICIENCY | SEEGENE INC (KR) | 2023-11-22 | — | — | EP | claimed |
| EP-3286338-B1 | AMPLIFICATION WITH PRIMERS OF LIMITED NUCLEOTIDE COMPOSITION | Atila Biosystems Incorporated (US) | 2023-11-01 | — | — | EP | claimed |
| CN-110168103-B | Methods for reducing primer dimer formation and increasing amplification efficiency | SEEGENE株式会社 | 2023-09-08 | — | — | CN | claimed |
| US-20230250474-A1 | SAMPLE PREPARATION METHOD | OXFORD NANOPORE TECHNOLOGIES PLC (GB) | 2023-08-10 | — | — | US | claimed |
| US-20050164184-A1 | Hybridization portion control oligonucleotide and its uses | SEEGENE, INC. (KR) | 2005-07-28 | — | — | US | claimed |
| WO-2005045073-A1 | METHOD FOR AMPLIFYING UNKNOWN DNA SEQUENCE ADJACENT TO KNOWN SEQUENCE | SEEGENE, INC. (KR) | 2005-05-19 | — | — | WO | claimed |
| CN-1602361-A | Hybridization portion control oligonucleotide and use thereof | SEEGENE INC (KR) | 2005-03-30 | — | — | CN | claimed |
| CN-1578841-A | Annealing control primer and use of the same | VISION GENE CO LTD (KR) | 2005-02-09 | — | — | CN | claimed |
| EP-1448795-A1 | HYBRIDIZATION PORTION CONTROL OLIGONUCLEOTIDE AND ITS USES | Seegene, Inc. (KR) | 2004-08-25 | — | — | EP | claimed |
| EP-1448793-A1 | ANNEALING CONTROL PRIMER AND ITS USES | Seegene, Inc. (KR) | 2004-08-25 | — | — | EP | claimed |
| US-20030175749-A1 | Annealing control primer and its uses | SEEGENE, INC. (KR) | 2003-09-18 | — | — | US | claimed |
| US-20030119016-A1 | Antisense oligonucleotides with increased RNase sensitivity | THIRD WAVE TECHNOLOGIES, INC. | 2003-06-26 | — | — | US | claimed |
| WO-2003050306-A1 | HYBRIDIZATION PORTION CONTROL OLIGONUCLEOTIDE AND ITS USES | SEEGENE, INC. (KR) | 2003-06-19 | — | — | WO | claimed |
| WO-2003050305-A1 | ANNEALING CONTROL PRIMER AND ITS USES | SEEGENE, INC. (KR) | 2003-06-19 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12584168-B2 | Sample preparation method | POLN, POLRMT, POLM | TXNRD1 3056/4885TXNRD3 3966/4885TXNRD2 2319/4885 |
| US-12630851-B2 | Polynucleotide modification methods | PNP, NT5C3B, UNG | TXNRD1 2720/4885TXNRD3 3004/4885TXNRD2 1673/4885 |
| US-20030119016-A1 | Antisense oligonucleotides with increased RNase sensitivity | RNASE1, RNASEL, RNASEH1 | TXNRD1 1030/4885TXNRD3 627/4885TXNRD2 1552/4885 |
| US-12624387-B2 | Method for reducing primer dimer formation and increasing amplification efficiency | UBR4, UBAP2, UBAP2L | TXNRD1 1772/4885TXNRD3 1837/4885TXNRD2 1857/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.